Setting a Healthy Dialogue for Tumor and Immune Cells
Qrono’s pipeline therapies feature patentable combinations of active agents, biodegradable polymers and cell-sized particles that restore healthy signaling patterns to tumor and immune cells.
QR206 - Single agent therapy designed to maximize danger signal release as it kills cancer cells and associated regulatory cells from within an injected tumor. Goal: Low toxicity disease control for patients with inoperable local or regional tumors.
QR213 - Down-regulation inhibitor designed to safely increase systemic levels of cancer-specific T cells in patients recieving therapies, such as radiosurgery or toll-like receptor agonists, that activate antigen presenting cells. Goal: Enhance responses to checkpoint inhibitor immunotherapy for patients with solid tumors.